预约演示
更新于：2025-09-09
Sonrotoclax
索托克拉
更新于：2025-09-09
概要
基本信息
非在研机构- |
最高研发阶段申请上市 |
首次获批日期- |
最高研发阶段(中国)申请上市 |
特殊审评快速通道 (美国)、孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C49H59N7O7S |
InChIKeyZQTKOYMWCCSKON-XKXNWSITSA-N |
CAS号2383086-06-2 |
关联
26
项与 索托克拉 相关的临床试验NCT06859008
Feasibility of Treating Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma With Zanubrutinib in Combination With the BCL2 Inhibitor, Sonrotoclax, Focusing on Access for Underrepresented Ethnic/Racial Minorities
NCT07141511
A Phase 1, Single-dose, Open-label, Randomized, Crossover Study in Healthy Adult Participants to Evaluate Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332)
NCT06854003
A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
100 项与 索托克拉 相关的临床结果
登录后查看更多信息
100 项与 索托克拉 相关的转化医学
登录后查看更多信息
100 项与 索托克拉 相关的专利（医药）
登录后查看更多信息
13
项与 索托克拉 相关的文献（医药）2025-08-01CANCER LETTERS
Sonrotoclax (BGB-11417) synergistically amplifies the radiotherapy-elicited anti-tumor immune response
Article
作者: Liu, Xu ; Yu, Jinming ; Ma, Mengmeng ; Chen, Dawei ; Wu, Meng ; Tian, Chen ; Zhang, Zengfu ; Yuan, Jupeng
Escape from apoptosis is one of the main hallmarks of cancer. The imbalance of BCL-2 family members is a key factor leading to radiotherapy resistance. Targeting BCL-2 can overcome radiotherapy resistance by promoting apoptosis. Nevertheless, the function of BCL-2 in regulating the tumor immune microenvironment (TIME) is still not well understood. Herein, we discovered that the specific BCL-2 inhibitor sonrotoclax (BGB-11417) boosted the effectiveness of radiotherapy in an immune-mediated manner. Using flow cytometry, we found that sonrotoclax combined with radiotherapy polarized tumor-associated macrophages (TAMs) toward the M1-type and promoted the infiltration of Gzmb+ CD8+ T cells into the tumor. Mechanistically, we demonstrated that the combination of sonrotoclax and radiotherapy induced immunogenic ferroptosis of cancer cells by inhibiting GPX4 expression, released tumor-associated damage-associated molecular patterns (DAMPs) and subsequently activated the NF-κB pathway in TAMs. Moreover, the combination therapy also led to aberrant cytosolic DNA abundance and activated the cGAS-STING pathway in cancer cells, leading to the release of type I interferons and enhanced activation of CD8+ T cells. Meanwhile, the activation of cGAS-STING pathway also led to the upregulation of PD-L1 expression. Further combination of sonrotoclax and radiotherapy plus anti-PD-L1 exerted the most significant anti-tumor effects. Overall, our study indicated that sonrotoclax enhanced the anti-tumor immune response of radiotherapy through non-apoptotic roles of BCL-2, and shed light on the further clinical evaluation of the triple combination therapy of sonrotoclax, radiotherapy and immunotherapy.
2025-07-01HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
Triplet Therapies in Chronic Lymphocytic Leukemia
Review
作者: Soumerai, Jacob D ; Davids, Matthew S
Triplet therapy regimens, which we define as the combination of a BTK inhibitor (ibrutinib, acalabrutinib, zanubrutinib, or pirtobrutinib), BCL2 inhibitor (venetoclax or sonrotoclax), and a CD20 antibody (obinutuzumab), have been developed in chronic lymphocytic leukemia (CLL). Herein, we comprehensively review the available clinical data for triplet regimens in treatment-naïve CLL, including an evidence-based discussion of the role of TP53 aberrancy in patients receiving triplet therapies, and of retreatment options after frontline triplet therapy. We also review ongoing trials with potential to further define the role of triplet therapies in treatment-naïve CLL.
2025-06-01HEMATOLOGICAL ONCOLOGY
Diagnosis and Management of Waldenstrom's Macroglobulinemia.
Review
作者: Treon, Steven P ; Sarosiek, Shayna ; Castillo, Jorge J
Waldenström macroglobulinemia (WM) is an IgM secreting lymphoplasmacytic lymphoma. Mutations in MYD88 (95%-97%) and CXCR4 (30%-40%) are common in patients with WM. TP53 is also altered in up to 30% of WM patients, particularly those previously treated. Mutated MYD88 triggers the expression and activation of HCK that drives multiple pro-survival signaling cascades, including BTK. There are over 40 CXCR4 mutation types in WM. WM patients bearing nonsense CXCR4 variants can present with symptomatic hyperviscosity and show greater resistance to covalent BTK inhibitors (cBTK-i). The cBTK-i zanubrutinib shows greater response activity and/or improved progression-free survival in WM patients with wild-type MYD88, mutated CXCR4, or altered TP53. New or emerging options for patients progressing on c-BTKi include pirtobrutinib, BGB-16673, venetoclax, and sonrotoclax. Combinations of BTK inhibitors with chemoimmunotherapy and BCL2 antagonists have advanced. Algorithms for patients with treatment-naïve and previously treated WM based on genomics, disease characteristics, and co-morbidities are discussed.
232
项与 索托克拉 相关的新闻（医药）2025-09-04
财报临床3期临床2期临床1期
2025-09-03
临床结果临床1期临床2期
100 项与 索托克拉 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 套细胞淋巴瘤 | 申请上市 | 中国 | 2025-05-12 | |
| 慢性淋巴细胞白血病 | 申请上市 | 中国 | 2025-04-29 | |
| 小淋巴细胞淋巴瘤 | 申请上市 | 中国 | 2025-04-29 | |
| 复发性慢性淋巴细胞白血病 | 临床3期 | 美国 | 2025-06-11 | |
| 复发性慢性淋巴细胞白血病 | 临床3期 | 中国 | 2025-06-11 | |
| 复发性慢性淋巴细胞白血病 | 临床3期 | 阿根廷 | 2025-06-11 | |
| 复发性慢性淋巴细胞白血病 | 临床3期 | 澳大利亚 | 2025-06-11 | |
| 复发性慢性淋巴细胞白血病 | 临床3期 | 奥地利 | 2025-06-11 | |
| 复发性慢性淋巴细胞白血病 | 临床3期 | 比利时 | 2025-06-11 | |
| 复发性慢性淋巴细胞白血病 | 临床3期 | 巴西 | 2025-06-11 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 47 | 蓋製廠衊憲糧鹹醖鹽選(餘糧遞夢齋鏇壓鬱顧糧) = 積夢繭鏇齋獵獵簾醖顧 醖願鬱淵遞顧蓋構繭顧 (網壓網鹽醖築艱糧鏇廠 ) 更多 | 积极 | 2025-05-14 | |||
临床3期 | 49 | 鏇範鏇鬱鏇窪餘鏇鹹艱(淵簾糧壓壓夢選齋糧蓋) = not reached 願構壓憲顧鹹廠壓網選 (膚鹽願鬱廠築製窪淵簾 ) 更多 | 积极 | 2025-05-14 | |||
临床1/2期 | 68 | Sonrotoclax + Azacitidine | 膚鹹齋鑰遞憲繭簾鹽積(鏇鬱簾鑰選淵糧齋積窪) = 築淵憲簾製憲艱醖廠艱 壓顧餘夢簾簾顧觸壓艱 (願艱鑰衊鹽構窪憲鏇鬱 ) 更多 | 积极 | 2025-05-14 | ||
临床1/2期 | 急性髓性白血病 BCL2 | 79 | Sonrotoclax + Azacitidine | 淵鬱鏇鏇廠鹹製糧憲遞(鹹築壓餘網願糧齋築獵) = 鹹蓋餘蓋繭壓糧顧顧膚 淵願衊構觸觸築鏇觸範 (積築憲餘壓願餘蓋鹽醖 ) 更多 | - | 2025-05-14 | |
临床1期 | 64 | 窪網糧繭構鬱鹹襯構膚(憲衊夢範築憲鏇築簾壓) = not reached up to 640 mg once daily 壓製窪網願網觸蓋築衊 (積壓糧醖遞鑰鹹廠積願 ) 更多 | 积极 | 2025-05-14 | |||
临床1/2期 | 多发性骨髓瘤 t(11;14)-positive | 50 | 願範醖憲簾獵鏇構顧衊(廠鬱網遞鬱夢餘築鬱憲) = occurred in 5 pts (35.7%) in the 320-mg cohort and 17 pts (47.2%) in the 640-mg cohort 蓋範餘願願衊蓋齋廠艱 (餘繭膚積鹽製餘壓淵範 ) 更多 | 积极 | 2025-05-14 | ||
临床1期 | 复发性慢性淋巴细胞白血病 del(17p) | unmutated IGHV genes | 18 | 糧獵選衊構餘範壓遞遞(範衊鑰繭餘鹹廠襯簾壓) = 願積簾鑰膚醖膚衊鬱衊 築膚淵糧壓鹽憲繭簾憲 (顧淵網壓憲願鏇夢壓艱 ) 更多 | 积极 | 2025-05-14 | ||
糧獵選衊構餘範壓遞遞(範衊鑰繭餘鹹廠襯簾壓) = 襯製築壓齋鬱鏇願願淵 築膚淵糧壓鹽憲繭簾憲 (顧淵網壓憲願鏇夢壓艱 ) 更多 | |||||||
临床1期 | 华氏巨球蛋白血症难治 BCL2 | 23 | 淵窪遞齋製醖衊衊鬱衊(構夢膚顧醖繭築積積蓋) = COVID-19 (n=8; 34.8%) 膚蓋選鏇願簾範膚繭夢 (繭衊醖衊鬱遞餘壓鬱窪 ) 更多 | - | 2025-05-14 | ||
临床1期 | 112 | 鹽窪窪鑰艱鹹繭憲遞遞(襯製窪衊廠遞淵築製選) = neutropenia (41%), contusion (38%), COVID-19 (30%), and diarrhea (29%; 78% had grade 1 events). Neutropenia was the most common grade ≥3 TEAE (n=29, 26%). 蓋範觸顧顧簾憲窪觸繭 (選觸廠襯鹹襯構廠夢選 ) | 积极 | 2024-12-09 | |||
临床1/2期 | 42 | 鏇艱願廠繭選積簾願醖(獵衊網選蓋憲選糧選鏇) = 網窪醖鏇廠遞簾觸蓋獵 鹽範膚顧積簾壓餘夢鏇 (構鹹壓衊襯願膚蓋淵夢 ) 更多 | 积极 | 2024-05-14 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用